Unaudited Financial Results for the quarter and nine months ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts less than Nifty Microcap 250 and 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zenotech Laboratories reported Q3 FY26 revenue from operations of Rs 1,182.60 lakhs, up about 16% from Rs 1,022.16 lakhs in Q3 FY25. Nine-month revenue rose ~10% to Rs 3,069.70 lakhs. Profit after tax for Q3 stood at Rs 192.56 lakhs (vs Rs 169.28 lakhs YoY), but 9-month PAT nearly halved to Rs 207.87 lakhs from Rs 432.99 lakhs, mainly due to a one-time Rs 190.49 lakh tax adjustment and reversal of MAT credit (Rs 187.47 lakhs) and deferred tax (Rs 157.82 lakhs) recorded in Q2 under Section 115BAA. An exceptional charge of Rs 29.89 lakhs was booked in Q3 for the new Labour Codes. Statutory auditors GSKA & Co. issued an unqualified (clean) limited review report. The Board appointed Mr. Nikkhil Kothhari as Independent Director and reconstituted key committees following completion of Mr. Chintan Shah's tenure.
Revenue growth is healthy but bottom-line is weighed down by one-time tax-related adjustments and the new Labour Code charge, which may cause near-term earnings volatility; the clean auditor report and steady standalone pharmaceutical operations are positives. Shareholders should watch for sustained margin recovery in coming quarters.